Search the GHTC website

Global health R&D delivers for Oklahoma

US government investment in global health R&D has delivered

$9.8 million
to Oklahoma research institutions
100+ new jobs
for Oklahoma
Oklahoma's top USG-funded global health R&D institutions

Oklahoma's top USG-funded global health R&D institutions

University of Oklahoma
$6 million
Oklahoma State University
$3.8 million
Oklahoma industry in global health R&D

Oklahoma industry in global health R&D

Accele Biopharma
Location(s): Oklahoma City
Location(s): Oklahoma City
Location(s): Norman
Northbound Therapeutics
Location(s): Oklahoma City
Pamlico BioPharma
Location(s): Oklahoma City

Oklahoma's top areas of global health R&D by USG funding

Diarrheal diseases
Salmonella infections
Neglected tropical diseases
Global health R&D at work in Oklahoma

Researchers at the University of Oklahoma have discovered a new approach to block the malaria parasite from infecting mosquitoes. This important discovery could lead to a new vaccine. The researchers found that an antibody used against a key mosquito protein stopped the malaria parasite from invading mosquitoes. Vaccination with this protein could dramatically reduce the number of malaria cases around the world by preventing mosquitoes from transmitting the disease. Each year, more than 200 million people are infected with malaria and half a million die from the disease, most of whom are young children. Approximately half of the world’s population is at risk. Scientists are racing to create a malaria vaccine and new drug treatments before resistance to current antimalarials spreads.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: NIAID/NIH